The GLP is committed to full transparency. Download and review our Annual Report.

‘Young blood’ plasma treatments unproven, possibly dangerous, says FDA

| | February 22, 2019

Federal health regulators on [February 19] warned consumers against controversial “young blood” treatments — plasma infusions from young donors marketed for conditions such as Parkinson’s, Alzheimer’s, multiple sclerosis and post-traumatic stress disorder.

“There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product,” [said FDA commissioner] Scott Gottlieb.

Plasma is the liquid portion of the blood and contains proteins that help blood to clot. It’s used to replace low levels of blood proteins in a range of medical situations. For example, some patients with liver disease are unable to make the proteins required for blood to clot.

Related article:  Citing food safety concerns, Senator Chuck Schumer demands FDA release glyphosate study

Clinics have been springing up that offer young-donor plasma infusions as a rejuvenating, “anti-aging” therapy. The FDA statement did not name any specific company; it was accompanied by a safety communication designed to inform consumers. But the agency warned it will consider taking enforcement action — such as sending warning letters demanding corrective actions — against companies that “abuse the trust of patients and endanger their health with uncontrolled manufacturing conditions.”

Read full, original post: FDA warns consumers against ‘young blood’ plasma infusions for dementia, PTSD and other conditions

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend